Date closed: 4/12/2018
Value: See below
On April 12, 2018, Arbutus Biopharma Corporation (Arbutus), an industry-leading hepatitis B virus (HBV) therapeutic solutions company and Roivant Sciences Ltd. (Roivant) announced that they have entered into an agreement to launch Genevant Sciences (Genevant), a jointly-owned company focused on the discovery, development, and commercialization of a broad range of RNA-based therapeutics. Under the terms of the agreement, Roivant will contribute $37.5 million in transaction-related seed capital for Genevant.
BLG acted as Canadian counsel to Arbutus with a team led by Warren Learmonth, that Stephen Robertson (Corporate), Randy Morphy (Tax) and Steve Winder (Employment).